 **Specifications TableSubject**Management of Technology and Innovation**Specific subject area**Technological alliances, innovation value.**Type of data**Tables**How data were acquired**First, data were collected from the USPTO database using the specialized software Matheo Patent XE® and then filtered, sampled and completes by the researchers.**Data format**Raw Filtered**Parameters for data collection**Data was extracted from the United States Patent and Trade Organization (USPTO) during the years 2006 to 2010. The sample consists of 340 joint patents from the biotechnology industry, including the number of forward citations to each joint patent in a time window of five years.**Description of data collection**Firstly, it was necessary to obtain all the biotechnology patents in the United States Patent and Trade Organization (USPTO) during the years 2006--2010. The second step consisted on extract the joint biotechnology patents from this database by checking and processing the number of patent applicants. Thirdly, a random sample method was used to select a subset in order to estimate characteristics of the whole population. This sample was rechecked and cleaned to improve the quality of data. Finally, a search and processing of forward citations received in subsequent patents in a time window of five years was made to each of the joint patents.**Data source location**Institution: United States Patent and Trade Organization (USPTO)Country: United States of America**Data accessibility**Repository name: MendeleyDirect URL to data: <https://data.mendeley.com/datasets/jcpj3xdhtt/draft?a=bafa219f-f1f1-4fe5-a459-2a2672c47930>

Value of the data {#sec0001}
=================

•The dataset provides information about joint patents which are not directly found in databases, specifically in the biotechnology sector. The data set can be used as a reference to the improve understanding about technological alliances or R&D collaboration and how partner technological attributes influence the value of the joint innovations.•Patent offices or patent organizations, firms from the biotechnology sector that have the will to develop potential strategic alliances, an managers and researchers will benefit from this data related to joint patents as a measure of firms collaborating in technological alliances.•Data can be used as a reference or baseline to develop comparative studies. Comparative studies should include analysis in terms of the value of the joint patent by means other than forward citations (e.g. economic value, private value); also, can be used as a reference to other databases different from the USPTO, such as the European Patent Office, or the Japan Patent Office to find differences and similitudes on the mechanisms used on those regions.

1. Data description {#sec0002}
===================

The dataset sample is composed of joint patents in the biotechnology industry. Patents in biotechnology industry are an indication of innovative success and the generation of new knowledge \[[@bib0001], [@bib0002]\]. The biotechnology joint patents in the data set are those that have the biotechnology classes according to the International Patent Classification -IPC- [@bib0003].

Each joint patent or co-patent shown in the dataset is defined as the patent owned by two or more firms [@bib0004] that form a duopoly or tight oligopoly comparable to a restrictive licensing agreement from an economic standpoint [@bib0005]. The joint patents in the dataset are considered a good measure of innovative output in an alliance \[[@bib0006], [@bib0007]\]. Following past research, the patents used in the dataset are those that have been successfully applied for [@bib0008].

In general, there is a distinction between the private value and the social value of inventions or patents [@bib0009]. The private value are the benefits perceived by the firm that has the patent compared to the firm that does not have it [@bib0010]. The social value embodies the total net value generated by the patent for social welfare [@bib0009]. The present dataset make use of one of the most used indicators of patent social value, the number of forward citations [@bib0011]. This indicator has been used already in valuing joint patents \[[@bib0004],[@bib0007],[@bib0012]\].

The dataset contains a sample of 340 joint patents (technological alliances) in the biotechnology industry with a total and average forward citation of 570 and 1.67 respectively, in a five-year window; the maximal forward citation made to a joint patent is 28 and the minimal forward citation for each year is cero. [Table 1](#tbl0001){ref-type="table"} shows a basic description of the aggregate data obtained per year.Table 1Aggregate information of joint patents data set by year from 2006 to 2010Table 1Year\# of joint patentsTotal Forward citationsMean Forward citationsMax Forward Citation200615261.7372007671742.59282008941591.69212009891511.6926201075600.87

[Fig. 1](#fig0001){ref-type="fig"} shows the boxplot by year of the forward citation variable. In all the years, the forward citations received by the joint patents are more disperse between the 50% (Q2) and the 75% (Q3) of the dataset. There is always a concentration in the first 25% of the data. According to this figure, the mean is always bigger to the median in all the years. The year 2007 offers the bigger dispersion and according to [Table 1](#tbl0001){ref-type="table"} is the year with the bigger forward citation indicator. However, 2008 is the year with the higher number of joint patents. The years 2007, 2008, 2009, and 2010 have outliers.Fig. 1Boxplot of forward citation for each year.Fig 1

[Fig. 2](#fig0002){ref-type="fig"} shows the forward citation distribution of the joint patents. Most of the joint patents from the sample (56%) are not cited at all, 15% are cited once, 8% are cited twice, and 3% are cited three times, and only 4% of the joint patents are cited equall or greater than 10 times. This figure shows how skewed is the distribution of the count dependent variable.Fig. 2forward citation (joint value) frequency distribution.Fig 2

The Appendix A shows the complete dataset that includes the year of application, the application number, the 5-year forward citation, the International Patent Classification codes for the biotechnology industry, and the pair of firms that are assignees of each one of the joint patents. Appendix B shows the complete raw data from which the dataset was sampled.

2. Experimental design, materials, and methods {#sec0003}
==============================================

The dataset is obtained from the joint patents in the biotechnological industry. The time frame used ranges from the years 2006 to 2010. Data were obtained from joint technological patents according to the International Patent Classification [@bib0003]. The technological codes or classes used to filter the patents are: A01H1/00, A01H4/00, A61K38/00, A61K39/00, A61K48/00, C02F3/34, C07G(11/00, 13/00,15/00), C07K(4/00,14/00,16/00,17/00,19/00), C12M, C12N, C12P, C12Q, C12S, G01N27/327, G01N33/(53\*,54\*,55\*,57\*,68,74,76,78,88,92). [Table 2](#tbl0002){ref-type="table"} offers a description of the IPC codes used to obtain the dataset for the biotechnology industry.Table 2International patent classification code description for biotechnology patents [@bib0003]Table 2IPC codesDescriptionA01H 1/00Processes for modifying genotypesA01H 4/00Plant reproduction by tissue culture techniquesA61K 38/00Medicinal preparations containing peptidesA61K 39/00Medicinal preparations containing antigens or antibodiesA61K 48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapyC02F 3/34Biological treatment of water, waste water, or sewage: characterized by the microorganisms usedC07G 11/00Compounds of unknown constitution: antibioticsC07G 13/00Compounds of unknown constitution: vitaminsC07G 15/00Compounds of unknown constitution: hormonesC07K 4/00Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereofC07K 14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereofC07K 16/00Immunoglobulins, e.g. monoclonal or polyclonal antibodiesC07K 17/00Carrier-bound or immobilized peptides; Preparation thereofC07K 19/00Hybrid peptidesC12MApparatus for enzymology or microbiologyC12NMicro-organisms or enzymes; compositions thereofC12PFermentation or enzyme-using processes to synthesize a desired chemical compound or composition or to separate optical isomers from a racemic mixtureC12QMeasuring or testing processes involving enzymes or micro-organisms; compositions or test papers therefor; processes of preparing such compositions; condition-responsive control in microbiological or enzymological processesC12SProcesses using enzymes or micro-organisms to liberate, separate or purify a pre-existing compound or composition processes using enzymes or micro-organisms to treat textiles or to clean solid surfaces of materialsG01N 27/327Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means: biochemical electrodesG01N 33/53\*Investigating or analysing materials by specific methods not covered by the preceding groups: immunoassay; biospecific binding assay; materials thereforeG01N 33/54\*Investigating or analysing materials by specific methods not covered by the preceding groups: double or second antibody: with steric inhibition or signal modification: with an insoluble carrier for immobilizing immunochemicals: the carrier being organic: synthetic resin: as water suspendable particles: with antigen or antibody attached to the carrier via a bridging agent: Carbohydrates: with antigen or antibody entrapped within the carrier.G01N 33/55\*Investigating or analysing materials by specific methods not covered by the preceding groups: the carrier being inorganic: Glass or silica: Metal or metal coated: the carrier being a biological cell or cell fragment: Red blood cell: Fixed or stabilized red blood cell: using kinetic measurement: using diffusion or migration of antigen or antibody: through a gelG01N 33/57\*Investigating or analysing materials by specific methods not covered by the preceding groups: for venereal disease: for enzymes or isoenzymes: for cancer: for hepatitis: involving monoclonal antibodies: involving limulus lysateG01N 33/68Investigating or analysing materials by specific methods not covered by the preceding groups: involving proteins, peptides or amino acidsG01N 33/74Investigating or analysing materials by specific methods not covered by the preceding groups: involving hormonesG01N 33/76Investigating or analysing materials by specific methods not covered by the preceding groups: human chorionic gonadotropinG01N 33/78Investigating or analysing materials by specific methods not covered by the preceding groups: thyroid gland hormonesG01N 33/88Investigating or analysing materials by specific methods not covered by the preceding groups: involving prostaglandinsG01N 33/92Investigating or analysing materials by specific methods not covered by the preceding groups: involving lipids, e.g. cholesterol

The data was first filtered by finding the joint patent applications found in the United States Patent and Trade Organization -- USPTO- database. The USPTO has information on patent applications and all classes of patents such as utility, design, reissue, plant patents, and includes bibliographic data, full description of the invention and the claims. The USPTO was chosen because the United States is the country with the higher share in biotechnology patents filed under the Patent Cooperation Treaty -PCT\_ with a 40.94% [@bib0013]. Other databases like the European Patent Office were not mixed in the dataset, because the practices about patent processing are different between offices [@bib0014].

There is not direct way to obtain biotechnology joint patents from patent databases. To do so, the first step in this process was to obtain all the biotechnology patents no matter how many owners were assigned to them. This activity was made using the standalone software Matheo Patent XE® by means of a search equation based on the IPC codes assigned to the field. Matheo Patent XE® is a tool that search, analyses and make survey of patents. The search equation used in the analysis was the following:"*((ic:(A01H1) OR ic:(A01H4) OR ic:(A61K38) OR ic:(A61K39) OR ic:(A61K48) OR ic:(C02F3/34) ORic:(C07G11) OR ic:(C07G13) OR ic:(C07G15) OR ic:(C07K4) OR ic:(C07K14) OR ic:(C07K16) ORic:(C07K17) OR ic:(C07K19) OR ic:(C12M\*) OR ic:(C12N\*) OR ic:(C12P\*) OR ic:(C12Q\*) OR ic:(C12S\*)OR ic:(G01N27/327) OR ic:(G01N33/53) OR ic:(G01N33/531) OR ic:(G01N33/532) OR ic:(G01N33/533)OR ic:(G01N33/534) OR ic:(G01N33/535) OR ic:(G01N33/536) OR ic:(G01N33/537) OR ic:(G01N33/538)OR ic:(G01N33/539) OR ic:(G01N33/54) OR ic:(G01N33/541) OR ic:(G01N33/542) OR ic:(G01N33/543)OR ic:(G01N33/544) OR ic:(G01N33/545) OR ic:(G01N33/546) OR ic:(G01N33/547) OR ic:(G01N33/548)OR ic:(G01N33/549) OR ic:(G01N33/55) OR ic:(G01N33/551) OR ic:(G01N33/552) OR ic:(G01N33/553)OR ic:(G01N33/554) OR ic:(G01N33/555) OR ic:(G01N33/556) OR ic:(G01N33/557) OR ic:(G01N33/558)OR ic:(G01N33/559) OR ic:(G01N33/57) OR ic:(G01N33/571) OR ic:(G01N33/572) OR ic:(G01N33/573)OR ic:(G01N33/574) OR ic:(G01N33/575) OR ic:(G01N33/576) OR ic:(G01N33/577) OR ic:(G01N33/578)OR ic:(G01N33/579) OR ic:(G01N33/68) OR ic:(G01N33/74) OR ic:(G01N33/76) OR ic:(G01N33/78) ORic:(G01N33/88) OR ic:(G01N33/92))*"

In order to filter actors in the patents different from firms, the "inventor" filter was used, followed by the filter equation:"*not APP/univ\* and not APP/empty and not APP/colle\* and not APP/inst\* and not APP/center and not APP/hospital\**"

The results from the software offered data that included joint and single owner patents. Therefore, the second step consisted on extracting only the joint biotechnological patents from this initial data. To do so, was necessary to filter the patents that had more than one applicant in the applicant field, this was done by the authors using a spreadsheet of Microsoft Excel®. The total number of joint patents in the biotechnological field was 1931 (Appendix B). This set of joint patents is the universe of the research. A simple random sampling method was used to select a subset to estimate characteristics of the whole population. The resulting sample size was 465 joint patents.

The 465 joint patents were cleaned with high detail in order to overcome problems like incomplete or confused information or when they belonged to organizations or actors different from firms. The resulting sample of joint patents after cleaning was 340 patents which is the dataset used (Appendix A). In order to obtain a 5% of margin error, 95% of confidence level and a response distribution of 50%, the sample of joint patents would have been of 320. Once the 340 biotechnological joint patents were obtained, was necessary to find the forward citation to each one of them; in other words, the number of citations received by each joint patent application in the next five years from the application date. Consequently, the forward citations were collected from the years 2006 to 2014.
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